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Pharmacological inhibition of gastric acid secretion and subsequent hypergas-
trinemia in Mastomys natalensis is an experimental model well suited for the
study ofgastric carcinoid formation. The genetic susceptibility ofMastomys to
develop such tumors is afeature reminiscent ofthe situation inpatients with the
MEN-l Zollinger Ellison syndrome, in whom tumor-induced hypergastrinemia
promotes the development of gastric carcinoids. Chronic hypergastrinemia,
induced by the irreversible H2-receptor antagonist loxtidine will causecarcinoid
formation in Mastomys already after four to six months. As in humans, gastric
carcinoids in Mastomys are mainly composed of enterochromaffinlike (ECL)
cells and have low malignant potential. Administration ofexogenous gastrin to
normal young animals increases the expression of histidine decarboxylase
(HDC) mRNA in the oxyntic mucosa within 30 minutes. Endogenous hyper-
gastrinemia, induced by short-time loxtidine treatment (three to 29 days)
enhances the expression ofHDC mRNA, histamine contents andECLcell num-
bers in the oxyntic mucosa. Long-term loxtidine treatment (seven to 21 months)
results in sustained hypergastrinemia and tumor formation. Tumor-bearing ani-
mals exhibited an increase in HDC mRNAand histamine content in the oxyntic
mucosa as well as increased urinary excretion ofthe main histamine metabolite,
tele-methylimidazole acetic acid (MeImAA). Subsequent to cessation of loxti-
dine treatment for two weeks, all parameters ofhistamine metabolism were nor-
malized in tumor-bearing animals. These results indicate that gastric carcinoids
developing during hypergastrinemia are well-differentiated neoplasms whose
histamine synthesis and metabolism is regulated by plasma gastrin.
INTRODUCTION
In recent years, great interest has been focused on the pathogenesis ofhuman gastric
carcinoids, their early diagnosis and optimal treatment [1, 2, 3]. Our understanding ofthe
mechanisms behind gastric carcinoid has been promoted by access to a suitable animal
model forinduction ofgastric carcinoids inMastomys natalensis [4]. Originally, Mastomys,
"the multimammate mouse," was used as a vector for tropical diseases, i.e., Lassa fever,
bilharzia and plague [5]. It was soon discovered that a laboratory strain ofMastomys was
prone to develop gastric tumors [6, 7]. At first, these tumors were described as adenocar-
cinomas, but later they were shown to originate from histamine producing enterochro-
maffin like (ECL)e cells and, therefore, were reclassified as gastric carcinoids. Several
strains of Mastomys have been characterized. The Z strain develops spontaneous antral
adenocarcinomas and fundic carcinoids, while the Y strain, like the wild type, develops
solely fundic carcinoids [8, 9]. Thegastric carcinoids inMastomys have shownthe capacity to
grow after transplantation to both Mastomys and nude mice [8-13]. Spontaneous formation
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ofgastric carcinoids increase with increasing age inMastomys. Some authors have report-
ed an incidence ofcarcinoids as high as 40-60 percent in older animals (one to two years
ofage) [14]. The malignant potential ofthe tumors varies significantly between strains. In
our own colony ofMastomys natalensis, we have not observed spontaneous development
of a gastric carcinoids within the first year of age [7].
INDUCTION OF TUMORS
The morphological changes occurring during spontaneous tumor formation have
been described in detail by Soga and collaborators [14]. During stage I, the ECLcells pro-
liferate within the basal portion ofthe fundic glands with chain formations (linear hyper-
plasia). During the pre-neoplastic stage II, the ECL cells form nodules, which are still
located within the gland (nodular hyperplasia). The neoplastic stage III comprises ECL
growth across the basal lamina of the gland into the lamina propria as well as formation
ofmicro- and macrocarcinoids. Adetailed staging and classification ofhuman gastric car-
cinoids was initiated by Solcia et al., and the classification has been successfully applied to
this animal model [7, 15, 16]. The principal differences compared to the original staging
are that isolated tumor growth in the lamina propria is referred to as dysplasia and that
microcarcinoid formation is required for classification ofthe lesion as neoplasia.
The rate at which the tumors are formed can be greatly enhanced by hypergastrinemia.
Administration ofthe insurmountable H2-receptor blocker loxtidine to the drinking water
reproducibly induces hypergastrinemia both in rats and Mastomys. The mechanism
involves blockade ofparietal H2-receptors, resulting in decreased secretion ofgastric acid
and subsequent sustained hypergastrinemia due to loss of feed back-control of antral G
cells [7, 17, 18]. Mastomys, subjected to long-term loxtidine treatment (2 g/l drinking
water), develop gastric carcinoids composed of ECL cells in a reproducible manner.
Neoplastic changes (micro- or macrocarcinoids) occur in about 25 percent and dysplastic
changes occur in about 50 percent of the animals subjected to loxtidine treatment for 24
weeks (classified according to Solcia et al.) [15]. The formation of tumors is to a certain
extent reversible. If loxtidine is administered for 24 weeks and thereafter withdrawn and
followed by drinking water alone for another 24 week period, the plasma gastrin levels
return tonormal andpractically all morphological changes up to the stage ofdysplasia dis-
appear during this second period. However the vast majority ofneoplastic lesions remain
unchanged [16]. This indicates that the neoplastically transformed ECL cells are less sen-
sitive to the trophic effects ofcirculating gastrin than normal or hyperplastic ECL cells.
RELEVANCE OF THE MASTOMYS MODEL
TheMastomys model is in several aspects well suited forthe study ofgastric carcinoids.
Firstly, the induction of carcinoids is much more rapid and results in higher incidence of
tumors than in other species, e.g., the rat [7, 17, 18, 19]. Secondly, the tumordevelopment
in Mastomys shows considerable similarity to the formation of type I (associated with
chronic atrophic gastritis, ACAG) and type III (associated with the MEN-I Zollinger-
Ellison syndrome) gastric carcinoids in man. Moreover, the animals are easy to maintain and
reproduce well in captivity. In both man andMastomys these tumors are mainly composed
ofECL cells [1, 2]. Furthermore, the tumors are oflow malignant potential and appear in
multiple foci together with precursor lesions (precarcinoids) throughout the entire oxyntic
mucosa in a background setting of linear and nodular hyperplasia. The inborn suscepti-
bility to hypergastrinemia inMastomys may correspond to the MEN-1 genetic trait, which
in man predisposes such patients to development of gastric carcinoids in response to the
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hypergastrinemia generated by the gastrinoma. Both for ACAG- and MEN-I associated
human gastric carcinoids, as well as for Mastomys tumors, a period of hypergastrinemia
is thus required for the tumor formation [20-24].
TISSUE DISTRIBUTION OF HISTAMINE AND METABOLIC PATHWAYS
The two major cellular sources of gastric histamine are the ECL cells and the mast
cells. The relative contribution ofhistamine from these sources vary between species [25].
In man, endocrine cells ofgastric mucosa (characterized by the presence ofchromogranin
A) are relatively few in comparison with the numerous mast cells. On the other hand, in
the rat, endocrine cells outnumber mast cells. In the Mastomys, the relative distribution of
these cells resembles that seen in the rat. The histamine-containing ECL cells constitute
the vast majority of the oxyntic endocrine cells (Figure 1), and from depletion studies in
the rat it has been estimated that ECL cells contribute at least 80 percent of the oxyntic
mucosal histamine [26]. In our own preliminary morphological studies inMastomys, mast
cells are very sparsely distributed within the fundic wall and thus appear to contribute
minimally to the tissue pool ofhistamine (Figure 2).
Histamine is formed by conversion of the amino acid histidine by the rate limiting
enzyme histidine decarboxylase (HDC). One physiological role of histamine released
from ECL cells is to stimulate the parietal cell to secrete gastric acid. In the hypergas-
trinemic state, stimulation ofthe ECLcells leads to activation ofHDC with enhanced produc-
tion of histamine, reflected by increased levels of mucosal histamine. Histamine can be
degraded by several different pathways. In man, although a small portion ofhistamine canbe
methylated and excreted as methylhistamine, the major pathway involves methylation and
oxidative deamination resulting in tele-methylimidazole acetic acid (MeImAA), which is
excreted in the urine. In rats, the methylation step is less important than in man. Non-
methylated ImAA is a less specific product since it can also be generated by metabolism of
histidine. A very small portion ofhistamine may also be excreted unmetabolized [27, 28].
HISTAMINE METABOLISM IN MASTOMYS NATALENSIS
As described above ECL cells in the gastric oxyntic mucosa ofMastomys are partic-
ularly sensitive to hypergastrinemia. They respond rapidly to elevated gastrin levels with
increased histamine synthesis, followed by ECL cell hyperplasia and formation ofgastric
carcinoids after sustained hypergastrinemia. Within 30 minutes of a single injection of
gastrin (500 pg/kg s.c.) an enhanced expression of HDC mRNA could be detected in the
oxyntic mucosa.
When animals were given oral loxtidine (10 g/l drinking water) for periods up to 29
days, sustained hypergastrinemia was induced. Plasma gastrin levels were significantly
elevated in all loxtidine-treated animals compared to untreated controls and reached a
peak after 14 days oftreatment (10-fold increase), which declined somewhat after 29 days
of treatment. The expression of oxyntic mucosal HDC mRNA was significantly elevated
(two to four times) in all loxtidine-treated animals, and a significant positive correlation
between the plasma gastrin levels and the mucosal HDC mRNA was evident (Figure 3).
To investigate the importance of plasma gastrin levels on mucosal HDC mRNA
expression and histamine metabolism in gastric carcinoids of Mastomys, two separate
groups of animals were given loxtidine for seven to 21 months. This resulted in prolonged
sustained hypergastrinemia and tumor formation. In one group, the long-term loxtidine
treatment was discontinued, and the animals thereafter received standard drinking water
without loxtidine for a period of two weeks before sacrifice. In both groups, only animals
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Figure 1. Consecutive sections of the
fundic wall inMastomys harboring a small
intramucosal carcinoid tumor. Following
24 hr of EDAC fixation the sections were
stained with a) antisera against histamine
(Delichon Ltd Finland no 2121 C dii
1:80000); b) HDC (Euro-Diagnostica, the
Netherlands, no B 260, 1 dii 1 5000); c) and
chromogranin A+B, (Euro-Diagnostica, the
Netherlands, no B 3151 dii 1500) respec-
tively. The vast majority of chromogranin
immunoreactive cells were also demonstrated
to display HDC and histamine immunoreacs
tivities, indicating that the majority of the
endocrine cells of the oxyntic mucosa were
ECL cells.
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Figure 2 a) Representative sections of the
normal oxyntic mucosa of Mastomys fol-
lowing 24 hr of EDAC fixation and stain-
ing with histamine antiserum (Delichon
Ltd, Finland, no 2121 C, dii. 1:80000) [42].
There are numerous histamine-immunoreac-
tive ECL cells located in the basal portion of
the glands as well as very few histamine-
immunoreactive mast cells in the submucosa.
b) Following 4 hr of IEFAA fixation the sec-
tion was stained with toluidine blue with
specific staining of the mast cells [43, 44].
Note the discrepancy in cell number between
the two cell types.Koliby et al.: Gastric carcinoid
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Figure 3. Effect of short-term loxtidine treatment (10 g/l drinking water) on plasma gastrin
levels and oxyntic mucosal expression of HDC mRNA. Four groups of animals were given lox-
tidine for periods up to 29 days, resulting in mild hyperplasia ofmucosal ECL cells. Plasma gastrin
levels were significantly elevated after three days and reached a maximum after 14 days compared
with untreated controls (c). The expression of HDC mRNA was also significantly elevated after
three days and reached a peak at seven days of treatment. There was thus a significant correlation
between circulating plasma gastrin levels and the mucosal expression of HDC mRNA.
with gross, macroscopic tumors were included. In the group still receiving loxtidine at
sacrifice, the plasma gastrin levels remained elevated. A concomitant increase in mucosal
HDC mRNAexpression, mucosal histamine levels and urinary excretion ofMeImAA was
observed. In contrast, in the group of animals receiving only water (no loxtidine) for two
weeks prior to sacrifice, the plasma gastrin levels had returned to levels seen in untreated
controls. This normalization ofplasma gastrin levels was accompanied by a simultaneous
normalisation ofmucosal HDC mRNAexpression, mucosal histamine levels and ofurinary
excretion of MeImAA (Table 1).
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Table 1.
C TL TW
Plasma gastrin (pM) 51.7 + 9.5 102.1 + 25.1 50.1 + 10.5
(n=7) (n.s.,n=7) (n=7)
HDC expression (relative values) 1 4.9 + 0.77 1.6 + 0.56
(n=7) (p<0.001,n=7) (n=7)
Mucosal histamine (jg/g tissue) 6.0 + 3.0 24.7 + 2.2 6.1 + 0.93
(n = 3) (p < 0.05, n = 3) (n =5)
U-MeImAA (mmol/mol C) 17.9 + 2.0 33.0 + 4.1 19.5 + 1.0
(n= 12) (p<0.01, n = 32) (n = 8)
Mastomys subjected to long-term loxtidine treatment resulting in development ofgastric carcinoids.
Only animals with large, macroscopic tumors were included. C, control animals; TL, tumor-bearing
animals on loxtidine at sacrifice; TW, tumor bearing animals on water at sacrifice. Values are given
as Mean + S.E.M. Student's two-tailed test was used for statistical comparison.
COMMENTS
Our experiments in Mastomys have demonstrated that the HDC mRNA expression
and histamine metabolism ofthe gastric oxyntic mucosa are controlled by the plasma gastrin
levels, and in addition, that expression ofHDC mRNA can rapidly be induced by injection
of exogenous gastrin. Furthermore, in animals with ECL cell tumors, the plasma gastrin
levels are capable of modulating the HDC mRNA expression and histamine metabolism.
The histamine metabolism ofgastric ECL cells during formation ofgastric carcinoids
is a complex process influenced by many stimuli. Carcinoids in man, whether associated
with ACAG or the MEN-I Zollinger Ellison syndrome or in the available animal models
(rat and Mastomys) seem to require a period ofhypergastrinemia for tumor formation. In
man this period of hypergastrinemia may be several years, or even decades [20, 24, 29].
In the rat, gastric carcinoids develop during a period of one to two years of sustained
hypergastrinemia [17, 19]. In the Mastomys, the carcinoids are rapidly induced over a
period of four to six months with hypergastrinemia [7, 18]. Experimental hypergastrine-
mia may be accomplished in several ways including pharmacological reduction ofgastric
acid secretion, which is a reproducible method for the induction of hypergastrinemia and
is associated with increased histamine synthesis and ECL cell proliferation. In the rat, a
similar state has been achieved by direct infusion of gastrin via osmotic minipumps [30].
In this species, partial corpectomy also results in compensatory hypergastrinemia and
ECL cell proliferation [31]. Using in vitro systems with elutriated rat- and Mastomys-
ECL cells, gastrin causes a rapid release of histamine together with an enhanced HDC
activity and DNA synthesis [32-34]. There is thus substantial evidence for an important
role of gastrin in stimulating the ECL cells to increase both histamine synthesis and cell
proliferation. In gastrin-stimulated mucosa, the ratio between proliferating ECL cells and
non-proliferating somatostatin-producing D cells increases, leading to the possibility that
decreased inhibition by somatostatin on ECLcells may accentuate the effects observed [7].
There is a discrepancy between the plasma gastrin levels and the expression of HDC
mRNA between the different experimental situations. Thus, in experiments with an acute
injection ofgastrin, a very high peak in plasma gastrin levels (2000-4000 pmol/l) was fol-
lowed by a moderate increase ofHDC mRNAexpression (two-fold increase) compared to
the chronic situation, where hypergastrinemia sustained for three to 29 days caused an
increase in plasma gastrin (300-500 pmol/l) which was associated with a three to four-fold
increase in HDC mRNA expression. A possible explanation for this obsevation may be
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that gastrin exerts its action via indirect mechanisms. Thus, in a state ofhypergastrinemia
prolonged over months, we observed a different relation between the plasma gastrin levels
and the increase in HDC mRNAexpression, i.e., a relatively moderate increase in plasma
gastrin (100 pmolfl) was associated with a pronounced (five-fold) increase in HDC
mRNA expression. This effect may be explained by an upregulation of CCK-B/gastrin
receptors on the ECLcells during tumordevelopment, which has been identified in isolated
Mastomys ECLcells. Similarly other local growth factors such as TGF-amay be involved
[34]. The possibility that other non-humoral factors may be involved in this process has
not been excluded. The relative importance of neuronal stimuli seems to vary among
species. In the rat, vagal innervation has been showed to interact with gastrin in the troph-
ic control of ECL cells since in animals subjected to unilateral vagotomy the ECL cell
density decreased on the vagotomized side [35]. This contrasts to the findings in the
Mastomys, where unilateral vagotomy had no obvious influence on ECLcell density [36].
Nevertheless, in isolated ECL cell populations, neurotransmittors were demonstrated to be
highly effective modulators ofECL cell function [37].
The possibility ofhistamine as an intermediate growth factorhas also been discussed.
In favor of this theory is the observation that treatment with Hi-receptor blockers, e.g.,
cyproheptadine, decreases the ECLhyperplasia observed in response to hypergastrinemia
[38]. On the other hand, depletion of histamine from ECL cells using a-fluoromethylhis-
tamine resulted in an unchanged hyperplastic response to hypergastninemia [39]. Also,
different receptor subtypes, different binding sites of receptors or receptors in different
states of affinity, may use separate intracellular second messenger systems. This has been
noted for histamine release as compared to DNA synthesis in ECL cells stimulated with
gastrin [32]. It is also probable that activation ofdifferent somatostatin receptor subtypes,
expressed by the ECL cells, operates via separate second messenger systems [40]. In this
respect, separate subtypes of somatostatin receptors are involved in the secretory modu-
lation and proliferative regulation of other neuroendocrine tumors [41].
CONCLUSIONS
It could be concluded that the Mastomys is an animal model with unique biological
characteristics and is very well suited for the study of ECL cell physiology and ECL cell
tumor formation. Gastrin seems to be the single most important factor in controlling ECL
cell function, including synthesis and secretion of biogenic amines as well as ECL cell
proliferation. However the regulation of ECL cell function is complex, and other factors
such as locally produced growth factors or cytokines as well as neuronal stimuli may be
of importance. The Mastomys model is of great relevance because of its biological simi-
larities to the situation in humans suffering from MEN-I/Zollinger-Ellison syndrome and
will be ofimportance when trying to explore the complex ECL cell pathophysiology.
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